Study: During Pandemic, High Blood Pressure Control Declined

Hypertension control and management worsened during the early months of the COVID-19 pandemic, according to a new analysis conducted at three large health systems, led by Cedars-Sinai investigators.

The study, published in the journal Hypertension, showed that during the first eight months of the pandemic, patients with hypertension measured their blood pressure less frequently, and when they did, their blood pressure readings were less healthy. The findings demonstrate the importance of ensuring ongoing access to healthcare with telemedicine and home blood pressure monitoring during emergencies.

“We had a unique opportunity to examine the pandemic’s impact on hypertension management among a large, diverse group of people from three major cities,” said Hiroshi Gotanda, MD, PhD, an assistant professor of Medicine at Cedars-Sinai. “Our analysis revealed similar patterns among participants from three different regions and a variety of racial, ethnic and socioeconomic backgrounds.”

Cedars-Sinai in Los Angeles led a group of investigators from Columbia University Irving Medical Center in New York City and Ochsner Health in New Orleans that analyzed the electronic health records of hypertensive adults followed by the three health systems.

To ensure participants had received continued care before the pandemic, investigators selected individuals whose health records included at least one primary care visit with a diagnosis of hypertension between August 2018 and January 2019 and another visit between February 2019 and January 2020. Participants had to be at least 18 years or older before the pandemic began in early 2020.

The investigators analyzed blood pressure measurements from the health records of 137,593 study participants. They compared pre-pandemic data (August 2018-January 2020) with data collected early in the pandemic (April 2020-November 2020) after stay-at-home orders were issued in California, Louisiana and New York. They excluded a transition period (February 2020-March 2020) after the pandemic began but before stay-at-home orders went into effect.

The analysis of the combined data found that 77.8% of participants had controlled blood pressure before the pandemic—a systolic reading of less than 140 mmHg over a diastolic reading of less than 90 mmHg. During the pandemic, the proportion of participants with controlled blood pressure decreased by 3.43 percentage points. A trend toward increasing control that had been observed before the stay-at-home orders flattened during the pandemic.

The investigators observed a small but significant increase in both systolic and diastolic blood pressure, after adjusting for participant characteristics and normal seasonal fluctuations. Systolic blood pressure increased by 1.79 mmHg and diastolic blood pressure increased by 1.30 mmHg during the pandemic compared with the pre-pandemic period.

“A small increase like that at a population level can have a significant effect, sometimes leading to an increase in heart attacks and stroke,” Gotanda said.

The number of blood pressure measurements began to decline during the pandemic transition period, dropping substantially early in the pandemic, then gradually increasing later in 2020. Disruptions in blood pressure monitoring likely contributed to the worsening in blood pressure control. The authors also suspected that effects of the early pandemic, such as decreased physical activity, disrupted sleep, unhealthy diets, increased stress and limited access to healthcare also could have played a role.

The review extended similar findings from previous research by studying data from a diverse group of participants and examining detailed clinical information to control for underlying issues that might impact study results, such as other chronic health conditions that could affect blood pressure outcomes.

“It is critical to increase access to healthcare, potentially through telemedicine and home blood pressure monitoring, to mitigate disruptions in care during future large-scale emergencies,” said senior author Teryl Nuckols, MD, MSHS, director of the Division of General Internal Medicine in the Cedars-Sinai Department of Medicine. “We want to avoid compounding the effects of widespread disasters by creating additional public health crises.”

The study was funded in part by the National Heart, Lung, and Blood Institute of the National Institutes of Health.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version